These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24504055)

  • 1. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
    Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
    J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
    Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
    Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
    Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
    Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-6-phosphatase Expression-Mediated [
    Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
    Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
    Cheyne RW; Trembleau L; McLaughlin A; Smith TA
    Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
    Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
    Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
    Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
    Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
    Park SG; Lee JH; Lee WA; Han KM
    Nucl Med Biol; 2012 Nov; 39(8):1167-72. PubMed ID: 22901702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Mamede MH; Wada M; Doi R; Hosotani R; Imamura M; Konishi J
    J Nucl Med; 2002 Feb; 43(2):173-80. PubMed ID: 11850481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
    Zhao S; Kuge Y; Mochizuki T; Takahashi T; Nakada K; Sato M; Takei T; Tamaki N
    J Nucl Med; 2005 Apr; 46(4):675-82. PubMed ID: 15809491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.
    Paudyal B; Oriuchi N; Paudyal P; Higuchi T; Nakajima T; Endo K
    Cancer Sci; 2008 Feb; 99(2):260-6. PubMed ID: 18271924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma.
    Shim HK; Lee WW; Park SY; Kim H; Kim SE
    Oncol Res; 2009; 17(7):331-7. PubMed ID: 19408578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
    Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
    J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer.
    Tohma T; Okazumi S; Makino H; Cho A; Mochiduki R; Shuto K; Kudo H; Matsubara K; Gunji H; Ochiai T
    Hepatogastroenterology; 2005; 52(62):486-90. PubMed ID: 15816463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.
    Hamann I; Krys D; Glubrecht D; Bouvet V; Marshall A; Vos L; Mackey JR; Wuest M; Wuest F
    FASEB J; 2018 Sep; 32(9):5104-5118. PubMed ID: 29913554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer.
    Tong SY; Lee JM; Ki KD; Choi YJ; Seol HJ; Lee SK; Huh CY; Kim GY; Lim SJ
    Int J Gynecol Cancer; 2012 May; 22(4):654-8. PubMed ID: 22398711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT monitoring of β3 agonist-stimulated brown adipocyte recruitment in white adipose tissue.
    Park JW; Jung KH; Lee JH; Quach CH; Moon SH; Cho YS; Lee KH
    J Nucl Med; 2015 Jan; 56(1):153-8. PubMed ID: 25525187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.
    Engles JM; Quarless SA; Mambo E; Ishimori T; Cho SY; Wahl RL
    J Nucl Med; 2006 Apr; 47(4):603-8. PubMed ID: 16595493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
    van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
    J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
    Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.